Mydecine completely Completes the First-Ever Global Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial provide Chain

DENVER, March 01, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a growing biopharma business in the life sciences category focused on the investigation and development, manufacturing, and acceptance of alternate nature-sourced medication for conventional usage, has completed the world’s very first international appropriate export of dried psilocybin mushrooms.

In December 2020, the business announced the conclusion of its very first commercial harvest of 20 kilograms (44 pounds) of psilocybin mushrooms at an exclusive mycology-focused research and cultivation center in Jamaica. The initial delivery for the harvest has been gotten at Mydecine’s Canadian active Good production Practice (CGMP) facility, which includes a Health Canada Schedule 1 license that is dealer’s to it, allowing for legal import/export, research and development, cultivation, product development, and commercial sale of active psychedelic medicinal compounds.

“This milestone is significant to our 2021 goals as we are now able to access a quality source of much needed product for both our own research purposes, as well as provide CGMP psilocybin that is naturally-derived offer and move to other certified research facilities around the world. All of us has invested time that is significant with various government agencies to create and develop sound protocols to ensure a smooth flow of biomass that is in full compliance with all federal laws. This is the first and only solidified supply that is commercial of psilocybin mushrooms and now we think this supply string will open numerous doorways to potentially cooperate and be involved in initiatives we find potentially promising,” stated Joshua Bartch, CEO and Chairman of Mydecine. “We are making progress that is significant having the first IND number on a 99.9% pure psilocybin product that the synthetic form mimics. We believe our natural-sourced psilocybin, that is both significantly less costly and more efficient than the form that is synthetic will show to be an improved general choice to meet up with the economy need along with voids any and all sorts of prospective patent claims. This markings a milestone of satisfying in the vow of fabricating a totally straight and uninterrupted supply that is global.”

“In the most potent psychedelic mushrooms, psilocybin is typically only around 1% of its total mass. This means that as much as 99% of the mushroom is composed of vegetative matter plus other potential active compounds that are medicinal. At our lab, we now have currently found numerous other active substances split from psilocybin and psilocin from simply our initial mushroom analysis that is psychedelic. Based upon our preliminary studies, we believe that this could have more effective results than just single-molecule psilocybin that is synthetic. This supply string can give us unrestrictive access that is scalable numerous types of unique psychedelic mushroom species native to Jamaica. This should significantly increase our development and research and manufacturing efforts with a few of the greatest kinds of mushrooms we understand of,” said Damon Michaels, Mydecine’s Co-Founder and Chief working Officer.

He proceeded, “Throughout history we now have seen numerous historic circumstances concerning the utilization of psychedelic medication, way more the utilization of psychedelic mushrooms to be utilized as secure and efficient medicine that is therapeutic help improve mental injuries or expand one’s overall consciousness. Today we are able to take this form that is ancient of medication and set it with today’s technology to higher understand its ingredients and exactly how they specifically connect to the mind and human body to create the most effective, many controllable and success feasible. For Mydecine to help you to produce the entire world’s first appropriate supply that is global of nature-sourced psilocybin to not only meet its own needs, but to supply to other licensed research organizations, universities, and healthcare facilities around the world, we hope to finally break the barrier of stigma and help people obtain mainstream access to this sacred medicine and turn it back into a traditional therapy.”

About Mydecine Innovations Group
Mydecine Innovations Group™ (CSE: MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and vitality that is enhancing. The company’s world-renowned medical and systematic board that is advisory building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has access that is exclusive a full cGMP certified pharmaceutical manufacturing unit having the ability to import/export, cultivate, extract/isolate, and evaluate active mushroom substances with complete federal government approval through wellness Canada. Mydecine additionally runs away from a state-of-the-art mycology lab in Denver, CO to spotlight hereditary research for scaling cultivation that is commercial of (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable effectiveness that is clinical. Mydecine recognizes the duty related to psychedelic-assisted treatment and certainly will continue steadily to place it self as a long-term frontrunner over the spectral range of medical studies, research, technology, and supply that is global. Mydecine has also successfully completed acquisitions that are multiple its inception.

Learn more at: https://www.mydecine.com/ and follow us on Facebook, Twitter, and Instagram.

Mydecine Innovations Group Media connections
Anne Donohoe / Nick Opich
KCSA Strategic Communications
[email protected] / [email protected]
212-896-1265 / 212-896-1206

On behalf for the Board of Directors:
Joshua Bartch, leader Officer
[email protected]

Corp Communications:
Charles Lee, Investor Relations
[email protected]
+1 720-277-9879

For more information about Mydecine Innovations Group, Inc., please go to the Company’s profile on SEDAR at www.sedar.com or go to the Company’s site at www.mydecine.com.

The Canadian Securities Exchange has neither approved nor disapproved the articles of the news launch and takes no duty for the accuracy or adequacy hereof. This news release contains information that is forward-looking this is of Canadian securities regulations regarding the business and its own company, which relate with future occasions or future performance and mirror management’s present objectives and presumptions. Usually however constantly, forward-looking information could be identified by way of terms such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variants) of these content, or declare that particular actions, occasions or outcomes “may”, “could”, “would” or “will” be taken, happen or be performed. Such statements that are forward-looking management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the pandemic that is COVID-19 the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company’s ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company’s products. Even though the business has attempted to spot factors that are important could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and events that are future vary materially from those expected such information. These statements that are forward-looking made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.

This news release does not constitute an offer to sell securities and the Company is not soliciting an offer to buy securities in any jurisdiction in which offer that is such solicitation or purchase is illegal ahead of enrollment or certification underneath the securities regulations of these jurisdiction. This news launch will not represent an offer of securities accessible in america. These securities never have and certainly will never be registered under usa Securities Act of 1933, as amended, or any continuing state securities regulations and may even never be provided or offered in america or to a U.S. individual unless therefore registered, or an exemption from enrollment is relied upon.

Latest posts